As global markets navigated turbulence in early 2025, India stands out as a beacon of stability and growth. The nation’s stock market continues to demonstrate remarkable resilience, consistently scaling new peaks amid international headwinds. With cooling inflation boosting consumer spending power and increased government expenditure driving corporate earnings, the stage is set for what analysts predict will be a transformative year for Indian equities.
As FY26 promises to outperform FY25, several companies are emerging as potential champions of India’s next growth chapter, positioned to capitalize on the country’s robust economic momentum.
5 high potential stocks to watch in 2025
1. Zomato (Target: 319-325)
At the forefront of India’s digital transformation, Zomato continues to strengthen its market leadership in 2025. The company’s strategic expansion through Blinkit’s quick commerce and Hyperpure’s B2B solutions has created diverse revenue streams. With increasing internet penetration and evolving consumer preferences, StoxBox analysts highlight Zomato’s potential for exponential growth in India’s burgeoning digital economy.
2. Piramal Pharma (Target: 290-340)
Piramal Pharma’s three-pronged approach across CRDMO, Complex Hospital Generics, and Consumer Healthcare positions it strategically in the pharmaceutical sector. The company’s CRDMO segment is witnessing increased biotech funding and customer engagement. ICICI Securities notes that despite US Biosecure Act delays, the company’s targeted $2 billion revenue by FY30 with 25% EBITDA margins showcases strong growth potential.
3. Cipla (Target: 1700+)
Despite temporary setbacks in Lanreotide sales, Cipla maintains robust market positions with 15% share in Albuterol and 35% in gLanreotide. The company’s recent expansion of its sales force to 8,700 representatives, as noted by Axis Securities, signals aggressive growth plans for its Indian operations. With Q4FY25 sales expected to rebound, Cipla’s market position appears increasingly strong.
4. Metropolis (Target: 2200+)
Metropolis has demonstrated impressive performance through its B2C and wellness segments, particularly in the Mumbai market. The company’s strategic decision to phase out discounts has strengthened B2B growth. Trading at 47x/39x FY26/27E earnings estimates, companies projects an impressive EPS CAGR of 30% over FY24-27E, indicating strong growth potential.
5. Nippon AM (Target: 750-800)
Nippon AM has emerged as a significant beneficiary of the small and midcap rally, with its SIP market share more than doubling to 12.6% in Q2FY25. The company’s remarkable 67% growth in equity AUM over the past year outperforms peers like HDFC AMC and UTI AMC, showcasing its growing dominance in India’s asset management landscape.
